๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
NCT05780294Nasopharyngeal Carcinoma, Leucogen, Chemotherapy, Myelosuppression
Sun Yat-sen University
Phase 3
132
Guangzhou
2023-04-01
Recruiting
Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07055841Squamous Cell Carcinoma of Head and Neck
Xiuping Ding
Phase 2
69
Jinan
2023-04-01
Recruiting
Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors
NCT05749627Advanced Malignant Solid Tumors
The First Affiliated Hospital of Nanchang University
Not applicable
20
Nanchang
2023-04-01
Active, closed
Efficacy of taVNS Versus Sham Stimulation in Reduing Depressive Symptoms in Patients With Epilepsy: a Multi-center, Double-blinded, Randomized, 20-week, Parallel-arm, Superiority Study
NCT06794034Depressive Symptoms in Patients With Epilepsy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
158
Hangzhou, Jiaxing, Jinhua, Ningbo, Yiwu
2023-04-01
Active, closed
fMRI Study of the Neural Mechanism of rTMS in the Treatment of Nicotine Dependence
NCT06762535Tobacco Use Disorder, Repetitive Transcranial Magnetic Stimulation
Tang-Du Hospital
Not applicable
50
Xi'an
2023-04-01
Recruiting
Prolonged Progesterone to Prevent Preterm Birth From IVF - ET
NCT05787509Preterm Birth
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 4
100
Guangzhou
2023-04-01
Recruiting
Corona Virus Disease 2019 Cohort Study
NCT06927622COVID-19 Pneumonia, COVID-19 Pandemic, COVID-19
Shandong University
Observational
1,000
Jinan
2023-04-01
Recruiting
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
NCT05797467Colorectal Cancer, Chemotherapy Effect
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3
366
Guangzhou
2023-04-01
Recruiting
A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.
NCT05967949PTCL
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Nanjing
2023-04-01
Recruiting
Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)
NCT06031246Lung Adenocarcinoma, Lymph Node Metastasis
Fudan University
Phase 3
634
Shanghai
2023-04-01
Recruiting
Lenalidomide in the Treatment of Mucosal Behรงet's Syndrome
NCT05449548Oral Ulcer
Peking Union Medical College Hospital
Not applicable
42
Beijing
2023-04-01
Recruiting
A Study of TIL in Advanced Solid Tumors (DFGD)
NCT06488950Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1
30
Shanghai
2023-04-01
Recruiting
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma
NCT05752136Rectal Cancer
Sir Run Run Shaw Hospital
Phase 3
108
Hangzhou
2023-04-01
Recruiting
The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics
NCT05791604Prader-Willi Syndrome
Children's Hospital of Fudan University
Not applicable
60
Shanghai
2023-04-01
Active, closed
A Study of the Clinical Benefit of Tobramycin Inhalation Solution
NCT06106789Bronchiectasis, Cystic Fibrosis, Lung Infection
Qianfoshan Hospital
Observational
1,600
Jinan
2023-04-01
Recruiting
Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
NCT06102863Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I
Peking University People's Hospital
Phase 2
38
Beijing
2023-04-01
Recruiting
Clinical Efficacy and Safety of Robot-assisted Total Knee Arthroplasty
NCT06856356Osteoarthritis, Knee
The First Affiliated Hospital of University of Science and Technology of China
Not applicable
40
Hefei
2023-04-01
Recruiting
Efficacy and Safety of Sodium Oligomannate in the Prevention of PSCI
NCT05545605Ischemic Stroke
Nanfang Hospital, Southern Medical University
Not applicable
116
Guangzhou
2023-04-01
Active, closed
Brain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Their Correlation With Clinical Cognitive Scores.
NCT07011329Nasopharyngeal Carcinoma (NPC)
Hubei Cancer Hospital
Observational
60
Wuhan
2023-04-01
Not yet open
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
NCT05778097Prostate Cancer, Biochemical Recurrence, High Risk
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
103
Nanjing, Nantong
2023-04-01
Not yet open
A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone
NCT05813665Giant Cell Tumor of Bone
Shanghai JMT-Bio Inc.
Phase 3
146
Beijing
2023-04
Not yet open
ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy
NCT05822284Non-small Cell Lung Cancer
Second Xiangya Hospital of Central South University
Observational
50
Changsha
2023-04
Not yet open
A Study of KM602 in Patients With Advanced Solid Tumors
NCT05766527Advanced Solid Tumor
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
38
Beijing
2023-04
Not yet open
A Study of KM501 in Patients With Solid Tumors
NCT05804864Advanced Solid Tumors
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
96
Tianjin
2023-04
Recruiting
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
NCT05736978AML, MRD
Shanghai Tong Ren Hospital
Phase 2
58
Shanghai
2023-03-31
Recruiting
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
NCT05769010Metastatic Breast Cancer
Henan Cancer Hospital
Phase 2
150
Zhengzhou
2023-03-31
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
AstraZeneca
Phase 3
4,300
Baoding, Beijing, Changchun, Changsha, Chengdu, Chifeng, Dalian, Foshan
2023-03-31
Recruiting
FlashPoint Renal Denervation Under Columbus 3D Mapping System Guidance for Treating Hypertension
NCT05590871Hypertension
Shanghai Hongdian Medical CO., LTD
Not applicable
180
Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Harbin, Zhengzhou, Zhenzhou
2023-03-31
Recruiting
Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)
NCT06031181Lung Adenocarcinoma, Frozen Section, Sublobar Resection
Fudan University
Phase 3
390
Shanghai
2023-03-31
By invitation
HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
NCT05787418COVID-19
Huahui Health
Phase 3
1,200
Beijing, Shanghai
2023-03-31
Recruiting
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT05759793Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
12
Shanghai
2023-03-30
Recruiting
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
NCT05683717B-Cell Malignancies
TransThera Sciences (Nanjing), Inc.
Phase 1
37
Nanjing
2023-03-30
Active, closed
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
NCT05780567Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
1,946
Beijing, Guangzhou, Suining
2023-03-30
Recruiting
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
NCT05749588Triple-negative Breast Cancer
Fudan University
Phase 2
120
Shanghai
2023-03-30
Recruiting
Al18F-NOTA-LM3 PET/CT in Patients With TIO
NCT07366099Tumor-Induced Osteomalacia
Peking Union Medical College Hospital
Not applicable
40
Beijing
2023-03-30
Recruiting
Clinical Application of Wearable Magnet Tracking System for Capsule Endoscopes
NCT05546346Capsule Endoscopes
Qilu Hospital of Shandong University
Not applicable
10
Jinan
2023-03-30
Active, closed
Safety and Efficacy Study of NGGT002 in PKU Adult Subjects
NCT06061614Phenylketonurias
The First Affiliated Hospital of Bengbu Medical University
Phase EARLY_PHASE1
15
Bengbu
2023-03-30
Active, closed
PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI
NCT05457582Acute Coronary Syndrome, Hyperlipidemias, Percutaneous Coronary Intervention, Cardiovascular Events
Nanjing First Hospital, Nanjing Medical University
Not applicable
1,212
Nanjing
2023-03-30
Recruiting
Comparison of Intr-operative Neuromonitoring Technique in Trans-oral Endoscopic Thyroidectomy Vestibular Approach
NCT06801444Thyroidectomy
China Medical University Hospital
Observational
304
2023-03-29
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
614
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-03-29
Recruiting
SHengXIaN-QuYu DEcoction in Heart Failure With Reduced and Mildly Reduced Ejection Fraction
NCT05583773Heart Failure
China-Japan Friendship Hospital
Phase 4
336
Beijing, Baoding, Qinhuangdao, Gongyi, Yangzhou, Jining, Qingdao, Changzhi
2023-03-29
Active, closed
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
NCT05627557Childhood Idiopathic Nephrotic Syndrome
Hoffmann-La Roche
Phase 3
85
Beijing, Guangzhou, Hangzhou, Wuhan, Xi'an, Zhengzhou
2023-03-29
Recruiting
Total Neoadjuvant Treatment ยฑImmunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)
NCT06229041Rectal Cancer
Peking University Cancer Hospital & Institute
Phase 3
472
Beijing
2023-03-29
Recruiting
Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention
NCT04937699Acute Coronary Syndrome, Percutaneous Coronary Intervention
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
2,690
Hangzhou
2023-03-28
Recruiting
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
NCT06041776Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
Betta Pharmaceuticals Co., Ltd.
Phase 3
570
Beijing, Nanjing, Shanghai
2023-03-28
Recruiting
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05768529Relapsed or Refractory Non-Hodgkin's Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2
100
Changsha, Suzhou
2023-03-28
Active, closed
Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women
NCT06776055Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN - Cervical Intraepithelial Neoplasia
Shanghai Zerun Biotechnology Co.,Ltd
Observational
5,372
Lingchuan, Quanzhou, Xingโ€™an, Daming, Dingxing, Zhengding, Puyang, Wenquan
2023-03-27
Recruiting
Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation
NCT06050980NSCLC
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
220
Beijing, Chongqing, Fuzhou, Nanning, Harbin, Luoyang, Zhengzhou, Changsha
2023-03-27
Active, closed
Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy
NCT05694598Bietti Crystalline Dystrophy
Shanghai Vitalgen BioPharma Co., Ltd.
Phase 1
12
Shanghai
2023-03-27
Recruiting
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
NCT05718895Advanced/Metastatic Solid Tumors
Antengene Biologics Limited
Phase 1
156
Beijing, Chengdu, Fuzhou, Hefei, Jinan, Lanzhou, Qingdao, Shanghai
2023-03-27
Active, closed
650nm Low-level Red-light for Myopia Control and Prevention in Children
NCT05786586Myopia
Beijing Tongren Hospital
Not applicable
572
Beijing
2023-03-26
Active, closed
Long-term Immune Persistence of a Bivalent HPV Vaccine in Females From Study 311-HPV-1004
NCT07820241Human Papillomavirus Infection
Shanghai Zerun Biotechnology Co.,Ltd
Observational
348
Hezhou
2023-03-25
Recruiting
A Study of XZB-0004 in Patients With Solid Tumors
NCT05772455Advanced Solid Tumor, NSCLC
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
128
Shanghai
2023-03-24
Recruiting
LDL Cholesterol TARGETs in OLDer Patients (Ageโ‰ฅ75 Years) With ASCVD (TARGET OLD)
NCT05765370Atherosclerotic Cardiovascular Disease, Older Patients, LDL Cholesterol
China National Center for Cardiovascular Diseases
Not applicable
4,200
Beijing
2023-03-24
Recruiting
F573 for Injection for the Treatment of Liver Injury/Failure
NCT05689645Acute Liver Failure, Acute-On-Chronic Liver Failure
Beijing Continent Pharmaceutical Co, Ltd.
Phase 2
97
Beijing, Qingyuan, Shiyan, Huaihua, Pingxiang, Changchun, Binzhou, Heze
2023-03-24
Recruiting
The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
NCT05778253Lung Squamous Cell Carcinoma
Second Xiangya Hospital of Central South University
Observational
50
Changsha
2023-03-23
Recruiting
Safety and Efficacy of Preoperative SBRT and Radical Surgery for Soft Tissue Sarcoma of Extremities
NCT06760221Soft Tissue Sarcoma, Stereotactic Body Radiotherapy, Surgery
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
20
Hangzhou
2023-03-23
Recruiting
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors
NCT06056362Neuroendocrine Tumors
Peking Union Medical College Hospital
Phase 1/2
80
Beijing
2023-03-23
Active, closed
Focus-out Glasses on Emmetropization in Chinese Children
NCT05689567Emmetropization, Myopia, Hyperopia
Children's Hospital of Fudan University
Not applicable
160
Shanghai
2023-03-23
Active, closed
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guรฉrin (BCG) in Participants With BCG-naรฏve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202Bladder Cancer
Janssen Research & Development, LLC
Phase 3
1,135
Beijing, Changchun, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou
2023-03-23
Active, closed
A Phase I Clinical Study of the Safety๏ผŒ Tolerability๏ผŒPharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
NCT05781048Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
56
Shanghai
2023-03-23
Recruiting
Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old
NCT05709288Hemophilia B
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
9
Tianjin
2023-03-23
Active, closed
SeQuent ยฎ Please CIS for the Treatment of INtracranial Atherosclerotic Stenosis
NCT06047964Stroke, Intracranial Atherosclerotic Stenosis
B. Braun Medical International Trading Company Ltd.
Not applicable
281
Beijing, Harbin, Nanyang, Changchun, Jining, Qingdao, Shanghai, Taiyuan
2023-03-23
Recruiting
A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients
NCT05823285Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1
150
Shanghai
2023-03-22
Recruiting
Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma
NCT05789043Acral Melanoma
Peking University Cancer Hospital & Institute
Phase 3
140
Beijing
2023-03-21
Recruiting
Wenzhou Gestational Diabetes Cohort
NCT05794152Gestational Diabetes Mellitus, Intrauterine Hyperglycemia, Birth Outcome, Adverse, Nutrition, Healthy
Westlake University
Not applicable
300
Wenzhou
2023-03-21
Recruiting
A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
NCT05749432Solid Tumor
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1
51
Beijing
2023-03-20
Recruiting
CEUS Improves the Diagnostic Performance of SRSS of Thyroid Carcinoma
NCT06146764Thyroid Nodule, Thyroid Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
800
Guangzhou
2023-03-18
Recruiting
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
NCT05760378Triple-Negative Breast Cancer
Fudan University
Phase 3
223
Shanghai
2023-03-17
Recruiting
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
NCT05635487HER2-positive Breast Cancer
Shengjing Hospital
Phase 2
65
Shenyang
2023-03-16
Active, closed
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
NCT05624554Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC
Phase 3
300
Beijing, Chongqing, Guangzhou, Guiyang, Haikou, Zhengzhou, Wuhan, Changsha
2023-03-16
Recruiting
PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients
NCT05704166Acute Lung Injury, Prevention
Fujian Medical University Union Hospital
Phase 2
214
Fuzhou
2023-03-16
Recruiting
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
NCT06010342Solid Tumor
Teligene US
Phase 2
60
Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2023-03-16
Recruiting
Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
NCT05212454Breast Cancer, Chemotherapy Effect
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
400
Hanzhou
2023-03-15
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
AbbVie
Phase 3
520
Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-03-15
Recruiting
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
NCT05687357Gastric Cancer, Gastroesophageal-junction Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
140
Wuhan, Nanjing, Taiyuan
2023-03-15
Recruiting
Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases
NCT05768490Brain Metastases, Radiotherapy, EGFR Activating Mutation
Sun Yat-sen University
Phase 3
232
Guangdong
2023-03-15
Recruiting
Stage II/III Colorectal Cancer Recurrence
NCT06314958Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II, Colorectal Cancer Stage III
City of Hope Medical Center
Observational
400
Dalian
2023-03-15
Recruiting
The Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.
NCT07638774Locally Advanced or Metastatic Breast Cancer
Fudan University
Not applicable
324
Shanghai
2023-03-15
Recruiting
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
NCT05772273Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Not applicable
43
Suzhou
2023-03-15
Active, closed
Induction Lorlatinib in Stage III Non-small Cell Lung Cancer
NCT05740943Stage III NSCLC, Surgery
Guangdong Provincial People's Hospital
Phase 2
48
Beijin, Guangzhou, Changsha
2023-03-15
Active, closed
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
NCT05744427Advanced Solid Tumor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2
725
Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Haโ€™erbin, Hefei, Jinan
2023-03-15
Recruiting
Effect of the Combined Programme on Perioperative Anaemia๏ผˆCPPA๏ผ‰
NCT05353348Patient Blood Management, Cardiac Surgery, Iron Deficiency Anemia
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
110
Hangzhou
2023-03-15
Recruiting
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
NCT05766800Locally Advanced, Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
100
Shanghai
2023-03-14
Recruiting
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
NCT05760612Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab, RCB Classification 1-2
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
300
Guangzhou
2023-03-14
Active, closed
Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer๏ผˆGALAXY๏ผ‰
NCT05824325Breast Cancer
Fudan University
Phase 1/2
56
Shanghai
2023-03-14
Recruiting
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
NCT05671822HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
258
Shanghai
2023-03-14
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.
NCT05773586Anemia
Ascentage Pharma Group Inc.
Phase 1
105
Guangzhou
2023-03-13
Recruiting
BPH Global Registry
NCT05543200Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Sociรฉtรฉ Internationale d'Urologie
Observational
7,500
Hangzhou
2023-03-13
Recruiting
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
NCT05779917Pancreas Cancer, CAR-T Cell Therapy, Mesothelin, Solid Tumor, Adult
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2023-03-10
Recruiting
China Children Eye Study
NCT05770661Axial Length, Myopia, Child Development
Shanghai Eye Disease Prevention and Treatment Center
Observational
30,000
Shanghai
2023-03-10
Recruiting
Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer
NCT05640609Stomach Neoplasm
West China Hospital
Phase 1/2
57
Chengdu
2023-03-10
Recruiting
Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
NCT05965284ANCA-associated Vasculitis, Maintenance Therapy
Chinese SLE Treatment And Research Group
Phase 4
40
Beijing
2023-03-09
Recruiting
Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
NCT05751343Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2
55
Guangzhou
2023-03-09
Active, closed
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
NCT05735496Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
219
Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Shenyang, Xi'an
2023-03-09
Recruiting
The Study of ICP-248 in Patients With Mature B-cell Malignancies
NCT05728658Hematological Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
191
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhengzhou
2023-03-09
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
Guangzhou, Nanning, Cangzhou, Shijiazhuang, Tangshan, Xingtai, Daqing, Harbin
2023-03-09
Recruiting
Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
NCT06718205Esophageal Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2
112
Zhengzhou
2023-03-08
Recruiting
Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients
NCT06437158Lymphatic Malformation
West China Hospital
Phase 2
200
Chengdu
2023-03-08
Recruiting
OH2 Injection in Melanoma
NCT05868707Melanoma
Binhui Biopharmaceutical Co., Ltd.
Phase 3
340
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin
2023-03-08
Rows per page Showing 15501–15600 of 19052
Previous 154 155 156 157 158 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=156

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.